AI Article Synopsis
- Atrial fibrillation is increasingly studied but has limited data on young patients (ages 18-45), prompting this research to evaluate hospitalization trends and economic impact.
- The study analyzed data from 260,080 hospital admissions between 2005 and 2015, finding a general decline in atrial fibrillation admissions in this age group, but an increase in admissions among young females and certain racial demographics.
- The frequency of cardiovascular risk factors like hypertension, diabetes, and obesity has nearly doubled, leading to a rise in hospitalization costs from $7363 in 2005 to $7924 in 2015, indicating a need for better management of these risk factors.
Article Abstract
Introduction: Atrial fibrillation is the most frequently occurring and studied arrhythmia. There is a limited data on young patients presenting with atrial fibrillation.
Objective: The objective of this research article was to assess the trend of hospitalization, epidemiological characteristics and economic burden in the young adult, aged 18-45 years, presenting with atrial fibrillation.
Methods: Hospitalization data from the National Inpatient Sample between 2005 and 2015 were used to analyze prevalence of risk factors and financial burden in young adults with atrial fibrillation.
Results: From 2005 to 2015, a total of 260,080 admissions were included in the study. From 2005 to 2015, there was a decreasing trend of total admissions with atrial fibrillation among the age group of 18-45 years compared to total admissions due to atrial fibrillation and total population. However, there was an increasing trend of admission observed in young females, white and black population. The frequency of hypertension, diabetes and obesity among young adults admitted with atrial fibrillation nearly doubled from 2005 to 2015. There was also a marked increase in the frequency of obstructive sleep apnea, alcohol abuse and drug abuse among patients admitted with atrial fibrillation. Furthermore, there was an increase in the mean cost of hospitalization from $7363 in 2005 to $7924 in 2015, P < 0.001.
Conclusion: In conclusion, increased cardiovascular risk factors among young adult with admissions for atrial fibrillation warrants controlling of the risk factors to further curtail hospitalizations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrtlng.2020.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Net Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Importance: The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.
Objective: To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).
Design, Setting, And Participants: This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up.
Left atrial appendage velocity, association with inflammatory indices in non-valvular atrial fibrillation patients.
Future Cardiol
January 2025
Echocardiography research Center, Rajaie cardiovascular medical and research Center, Iran University of Medical Science, Tehran, Iran.
Introduction: Decreased left atrial appendage emptying velocity (LAAV) is a marker for thrombus formation. This study evaluates the association between LAAV and inflammatory indices in non-valvular atrial fibrillation (AF) patients.
Methods: The study population was 1428 patients with AF, 875 of whom enrolled.
Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
Eur Heart J
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Background And Aims: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.
Methods: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER).
Patients' views on stroke prevention for atrial fibrillation after an intracerebral haemorrhage: a qualitative study.
Eur J Cardiovasc Nurs
January 2025
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University, and Liverpool Heart and Chest Hospital, Liverpool, UK.
Aim: (i) To explore the attitudes of patients with atrial fibrillation (AF) towards oral anti-coagulation (OAC) for stroke prevention post-intracerebral haemorrhage (ICH) and (ii) to explore factors that influence patients' decision-making process for stroke prevention.
Methods And Results: Patients with documented diagnosis of AF and history of a non-traumatic ICH, who were eligible for long-term OAC were recruited from eight hospitals in England, using purposive sampling. Data were collected using semi-structured interviews and analysed using Framework analysis.
Economic impact associated with dronedarone use in patients with atrial fibrillation.
J Med Econ
January 2025
Sanofi, Bridgewater, NJ.
Objective/AimIn 2009, dronedarone was approved by the United States Food and Drug Administration based on results from the ATHENA trial (NCT00174785), which showed significant reduction of cardiovascular (CV) hospitalization and death in patients with atrial fibrillation (AF) randomized to dronedarone versus placebo. In 2020, a retrospective study by Goehring et al. showed CV hospitalizations and deaths were lower in clinical practice following initiation of dronedarone compared to other antiarrhythmic drugs (AADs) in patients with AF and atrial flutter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!